Antimicrobial Susceptibilities of Clinical Acinetobacter baumannii Isolates With Different Genotypes

Jundishapur Journal of Microbiology
Hatice Uludag AltunAli Pekcan Demiroz

Abstract

The treatment of Acinetobacter baumannii infections is difficult. Carbapenems, sulbactam, and colistin are the most effective antibiotics. The aim of this study was to evaluate the susceptibilities of genotypically different A. baumannii isolates to sulbactam, amikacin, netilmicin, meropenem, tigecycline and colistin. Isolates from various clinical samples of patients with hospital-acquired infections that were identified by the VITEK 2 Compact system in our hospital's microbiology laboratory between January 2010 and March 2012 were included in the study. To determine genetic relatedness of the isolates, the rep-PCR method was used. The broth microdilution method was used for amikacin, netilmicin, meropenem and colistin, while E-test was used for sulbactam and tigecycline. Among the 300 isolates, 30 were found to be genotypically different and were evaluated in terms of their antimicrobial susceptibilities. All isolates were susceptible to colistin. The susceptibility rates were 66.6%, 50%, 36.6%, 30%, and 10% for netilmicin, tigecycline, sulbactam, amikacin, and meropenem, respectively. For carbapenem resistant isolates, the susceptibility rates were 66.6%, 51.8%, 33.3%, and 25.9% for netilmicin, tigecycline, sulbactam, and am...Continue Reading

References

May 15, 1999·Journal of Clinical Microbiology·D M Olive, P Bean
Jun 29, 1999·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J RuizJ Gómez
Mar 27, 2001·The Journal of Antimicrobial Chemotherapy·M J Rodríguez-HernándezJ Pachón
May 17, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G Christopher WoodBradley A Boucher
Feb 14, 2006·International Journal of Antimicrobial Agents·Anna M Ferrara
May 20, 2006·Scandinavian Journal of Infectious Diseases·Emine AlpMehmet Doganay
Mar 14, 2007·The Journal of Antimicrobial Chemotherapy·Shiri Navon-VeneziaYehuda Carmeli
Sep 25, 2007·Diagnostic Microbiology and Infectious Disease·Edoardo CarrettoUNKNOWN APSI "Acinetobacter Study Group," Italy
Jun 4, 2013·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Yu-Chung ChuangShan-Chwen Chang

❮ Previous
Next ❯

Citations

Jan 6, 2018·International Journal of Environmental Research and Public Health·Clemens KittingerGernot E Zarfel
Nov 13, 2019·International Journal of Antimicrobial Agents·Vijay Singh GondilSanjay Chhibber

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
genotyping

Software Mentioned

DiversiLab

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.